Lifecome Biochemistry Co Ltd

Lifecome Biochemistry Co Ltd has a debt-to-equity ratio of 3.52, indicating a high level of leverage, and a current ratio of 0.37, suggesting limited short-term liquidity. The company's operating cash flow is positive at 63.51 million CNY, but its capital expenditure is negative at -119.04 million CNY, indicating significant investment in long-term assets.

The company's profitability is weak, with a return on equity of -17.08% and a return on assets of -3.16%. These figures are below the typical performance metrics for the pharmaceutical industry, which usually expects positive returns on both equity and assets.

Lifecome Biochemistry Co Ltd's revenue is primarily concentrated in its domestic market, with no disclosed international revenue segments. The company's financial data does not provide a breakdown of revenue by product lines or geographic regions, making it difficult to assess the diversification of its income sources.

The company's growth trajectory is uncertain, as it reported a net loss of 55.74 million CNY and an operating loss of 77.38 million CNY. There are no disclosed revenue growth figures for the current or next fiscal year, and the company's financial performance suggests a challenging outlook.

The company's risk profile is marked by medium liquidity risk and low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The company has not disclosed any recent dilution events or adjustments in its valuation metrics.

There are no recent filings or transcripts disclosed in the available data that provide additional insight into the company's operations or strategic direction. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.

Lifecome Biochemistry Co Ltd (002868.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic update provides a clearer structural definition of the company’s operational focus, establishing a baseline for sector-specific analysis. Concurrently, the company’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, suggesting limited immediate pressure from share issuance or similar capital structure changes. Liquidity risk, however, is assessed at a medium level. This distinction highlights a potential area of financial friction that may warrant closer monitoring compared to the more stable dilution outlook. These updates represent the initial establishment of key risk and classification metrics for Lifecome Biochemistry, moving from undefined states to actionable data points for investors tracking the firm’s position within the healthcare industry.

Net income improved by 68.5% year-over-year, signaling a significant reduction in losses compared to the prior period.

Operating income surged 69.4% year-over-year, demonstrating substantial improvement in core operational profitability metrics.

Free cash flow improved by 58.7% year-over-year, indicating better cash generation capabilities despite ongoing negative flows.

Long-term debt decreased significantly from CNY 1.12 billion to CNY 564.8 million, reducing leverage and financial risk.

Gross profit turned positive at CNY 15.2 million, reversing a previous loss of CNY 106.9 million.

The company carries a high credit risk flag, indicating significant concerns regarding its ability to meet obligations.

Debt-to-equity ratio stands at 3.52, placing it in the bottom quartile compared to pharmaceutical peers.

Free cash flow remains deeply negative at CNY -212.9 million, highlighting persistent cash burn issues.